The role of pancreatic stone protein as a prognostic factor for COVID-19 patients

Eur Rev Med Pharmacol Sci. 2022 Sep;26(17):6391-6395. doi: 10.26355/eurrev_202209_29666.

Abstract

Objective: The outbreak of Severe Acute Respiratory Syndrome-CoronaVirus 2 (SARS-CoV-2) has rapidly spread throughout the world straining health care systems. Several biomarkers indicate the presence of hyper-inflammation and evaluate the severity of the disease. Our aim was to investigate the prognostic value of pancreatic stone protein plasma concentration in patients with SARS-CoV-2 pneumonia.

Patients and methods: We prospectively studied 55 patients with acute SARS-CoV-2 pneumonia admitted to our tertiary hospital. Sepsis biomarkers, including pancreatic stone protein (PSP), were measured on admission. The role of these biomarkers in the prediction of in-hospital mortality (28 day) and length of hospital stay was investigated.

Results: Although Pancreatic stone protein did not have significant prognostic value for in-hospital mortality, there was a moderate accuracy for prolonged length of stay. The optimal cut-off value for prolonged hospital stay was 51 ng/dL (Sensitivity: 0.65, Specificity: 0.913).

Conclusions: Pancreatic Stone Protein on admission could accurately identify patients requiring prolonged hospitalization. The results of this study can serve as a strong early basis for future validation studies of such an innovative approach.

MeSH terms

  • Biomarkers
  • COVID-19* / diagnosis
  • Humans
  • Lithostathine* / chemistry
  • Lithostathine* / metabolism
  • Prognosis
  • SARS-CoV-2

Substances

  • Biomarkers
  • Lithostathine